Show simple item record

dc.contributor.authorTrapani, Dario
dc.contributor.authorConforti, Fabio
dc.contributor.authorDe Pas, Tommaso
dc.date.accessioned2020-05-25T12:50:45Z
dc.date.available2020-05-25T12:50:45Z
dc.date.issued2017
dc.identifier.citationTrapani D, Conforti F, De Pas T. Egfr inhibition in a pretreated sacral chordoma: a rolefor erlotinib? Case report and a brief review of literature. Translational Medicine @ UniSa 2017, 16(5): 30-33.it_IT
dc.identifier.issn2239-9747it_IT
dc.identifier.urihttp://www.translationalmedicine.unisa.it/indexit_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/4486
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2684
dc.description.abstractWe describe the case of a 69-year old male with an EGFR- positive Imatinib refractory sacral chordoma with synchronous lung metastases, treated with erlotinib, a first- generation EGFR inhibitor. After disease progression following firstline Imatinib and a combination therapy with everolimus plus metformin, we made a challenge with an EGFR tyrosine kinase inhibitor (EGFR TKI), erlotinib. Despite a brief clinical benefit, the patient presented a rapid clinical deterioration leading to death, after 8 weeks of treatment.it_IT
dc.format.extentP. 30-33it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectChordomait_IT
dc.subjectErlotinibit_IT
dc.subjectImatinib refractoryit_IT
dc.subjectSacral tumorit_IT
dc.titleEgfr inhibition in a pretreated sacral chordoma: a rolefor erlotinib? Case report and a brief review of literatureit_IT
dc.typeArticleit_IT
 Find Full text

Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record